Imperial College London

DrMohamedShamji

Faculty of MedicineNational Heart & Lung Institute

Reader in Immunology & Allergy
 
 
 
//

Contact

 

+44 (0)20 7594 3476m.shamji99 Website

 
 
//

Location

 

Room 111Sir Alexander Fleming BuildingSouth Kensington Campus

//

Summary

 

Summary

Dr Shamji completed his clinical scientist fellowship training in clinical immunology at the Chelsea & Westminster Hospital NHS Foundation Trust in London, United Kingdom (UK) in 2004. He then pursued his interest in translational research and completed his PhD studies in allergy and clinical immunology at the National Heart & Lung Institute, Imperial College London, UK in 2010. He established his research group (Immunomodulation and Tolerance group) within Allergy and Clinical Immunology at Imperial College lead by Professor Stephen Durham.

Dr Shamji has a specific interest in respiratory allergies, especially how disease-modifying treatments such as allergen immunotherapy, novel biologics and novel immunomodulators (Toll Like Receptor (TLR) 7 and Surfactant protein (SP)-D) affect immunologic (T, B cell and immunoglobulins) responses leading to induction of immune tolerance, as well as the investigation of novel surrogate/predictive biomarkers of clinical outcome following successful immunotherapy.

He is actively involved in evaluating novel approaches of allergen immunotherapy using modified hypoallergic form of allergen protein, subcutaneous immunotherapy in combination with novel adjuvants, sublingual immunotherapy, peptide immunotherapy, biologics plus allergen of interest strategies to improve safety, efficacy and induce immune tolerance to sensitising allergen.

This involves:

1) Designing human pre-clinical laboratory mechanistic studies to test allergenicity and immunogenicity of novel modified/hypoallergenic allergen and T/B cell peptides

2) Investigating immunologic mechanisms of immunotherapy in the context of clinical trials (in collaboration with Professor Stephen Durham, within Allergy and Clinical immunology (ACI) or contract research organisation (CRO), pharmaceutical or biotech companies).

In collaboration with Professor Adnan Custovic and Dr Paul Turner, Dr Shamji is  investigating mechanisms of desensitisation and tolerance induction following oral peanut/milk immunotherapy by translating his work from respiratory disease human models.

Dr Shamji’s research has resulted in multiple peer-reviewed publications in high impact journals in the field of Allergy. His publications in the Journal of Allergy and Clinical Immunology have been selected as editor’s choice. He has written two book chapters on mechanisms and biomarkers of AIT (Allergens and Allergen Immunotherapy: Subcutaneous, Sublingual, and Oral, Fifth Edition, CRC press).

He is one of the Module 3 lead for the the 4thyear Respiratory science course and an active member of Staff Student Liaison Group (SSLG). He lectures on postgraduate course (MSc Molecular Medicine and MSc Immunology course). He also teaches basic science to specialist registrars (SpRs) trainees in Allergy through lectures and workshops. He mentors, supervises, and motivates PhD, M.Sc., B.Sc. and UROP students within the Allergy & Clinical immunology section. He also informs mentees of relevant resources available within the college. He has been nominated by the Postgraduate office (NHLI) and supervisors to examine for the Early and Late Stage review for PhD student at Imperial College London (4 students). He has served as an international PhD examiner during a public defence in Aarhus, Denmark (June, 2015), Ghent, Belgium (Feb 2018) and Rotterdam Netherlands (June 2018). 

Dr Shamji chairs an EAACI-funded task force on biomarkers for monitoring allergen immunotherapy consisting of 17 international expert members who are leaders in the field of immunotherapy. The aim of the task force is to achieve a consensus on potential surrogate biomarkers that can be used in clinical trials to monitor efficacy of AIT in individual patients. In recognition of his expertise in the field of allergen immunotherapy mechanisms/biomarker, he has been invited to speak at plenary, keynote, symposia and expert discussion sessions and workshops at the European Academy Allergy and Clinical Immunology (EAACI), American Academy Asthma Allergy and Immunology (AAAAI) and the British Society of Allergy and Clinical Immunology as well as industry sponsored meetings.

He is Chair of the Scientific Program Committee for the European Academy of Allergy and Clinical Immunology (EAACI). He has been an AAAAI international Fellow since 2014 and a committee member for Immunotherapy, Allergen Standardization and Allergy Diagnostic interest section (IASAD) (2011-) and Immunotherapy, Rhinitis, Sinusitis, Ocular allergy and Cough (IRSOC) (2015-). He represents basic science on the British Society of Allergy and Clinical Immunology (BSACI) annual meeting programme planning committee. He was invited to become a senior affiliate memberof Royal College of Physicians.

His research has lead to several preclinical studies moving onto phase II and now phase III trial of allergen immunotherapy in collaboration with Biotech Tools SA. He is a principal investigator and co-investigator on MRC, immune tolerance network (ITN) and several industry funded projects.